Fresh2 Group Limited Stock price

Equities

FRES

US03635R2067

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.55 USD -3.51% Intraday chart for Fresh2 Group Limited -35.00% -38.20%
Sales 2021 17.99M 2.49M Sales 2022 12.04M 1.67M Capitalization 65.83M 9.11M
Net income 2021 -119M -16.46M Net income 2022 -102M -14.11M EV / Sales 2021 8.1 x
Net Debt 2021 22.46M 3.11M Net Debt 2022 8.8M 1.22M EV / Sales 2022 6.2 x
P/E ratio 2021
-0.89 x
P/E ratio 2022
-0.61 x
Employees 75
Yield 2021 *
-
Yield 2022
-
Free-Float 68.46%
More Fundamentals * Assessed data
Dynamic Chart
1 day-10.94%
1 week-16.14%
Current month+81.93%
1 month+62.81%
3 months-20.83%
6 months-50.00%
Current year-35.96%
More quotes
1 week
0.44
Extreme 0.443
0.83
1 month
0.30
Extreme 0.3
0.90
Current year
0.30
Extreme 0.2999
0.90
1 year
0.30
Extreme 0.2999
9.17
3 years
0.30
Extreme 0.2999
131.40
5 years
0.30
Extreme 0.2999
243.60
10 years
0.30
Extreme 0.2999
243.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 29 22-10-02
Founder 67 09-12-31
Chief Executive Officer 66 09-12-31
Members of the board TitleAgeSince
Director/Board Member 64 22-10-02
Director/Board Member 55 22-10-02
Chief Executive Officer 66 09-12-31
More insiders
Date Price Change Volume
24-03-28 0.55 -3.51% 83 192
24-03-27 0.57 -10.94% 139,038
24-03-26 0.64 -11.11% 75,176
24-03-25 0.72 -3.56% 85,215
24-03-22 0.7466 -11.77% 36,774

Delayed Quote Nasdaq, March 27, 2024 at 04:30 pm EDT

More quotes
AnPac Bio-Medical Science Co Ltd is a China-based biotechnology company focused on early cancer screening and detection. The Company markets and sells multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. In addition to early cancer screening and detection, its CDA technology assists physicians in cancer diagnosis, prognosis and recurrence. Its CDA technology provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company have established two clinical laboratories in China and one clinical laboratory in the United States. The Company is also engaged in providing technical solution and outsourcing consulting service focusing on the digital, internet, and Web3 transformation of start-ups and traditional enterprises.
More about the company
  1. Stock
  2. Equities
  3. Stock Fresh2 Group Limited - Nasdaq